Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Metastatic Solid Tumors 1Mesothelioma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hemorrhage 1Hematologic Diseases 1Head and Neck Neoplasms 1Gynecological Solid Tumors 1Fallopian Tube Neoplasms 1Diarrhea 1Colitis 1Childhood Solid Tumor 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Cell- and Tissue-Based Therapy × Clear all
NCT03506802 2020-07-24

NYSCT MM

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡